Skip to main content
  • Paul Scherrer Institut PSI
  • PSI Research, Labs & User Services

Digital User Office

  • Digital User Office
  • DE
  • EN
  • FR
Paul Scherrer Institut (PSI)
Suche
Paul Scherrer Institut (PSI)

Hauptnavigation

  • Our ResearchOpen mainmenu item
    • Current topics from our research
    • Matter and Material
    • Human Health
    • Energy and Environment
    • Large Research Facilities
    • Brochures
    • 5232 — The PSI magazine
    • Research Divisions & Labs (only english)
  • IndustryOpen mainmenu item
    • Overview
    • Technology Transfer
    • Expertise
    • Spin-off Companies
    • Park Innovaare
  • Proton TherapyOpen mainmenu item
    • Overview
    • Physician & Patient Information
  • CareerOpen mainmenu item
    • Overview
    • Job Opportunities
    • Working at PSI
    • Personnel Policy
    • Equal Opportunities, Diversity & Inclusion
    • Training and Further Education
    • Vocational Training
    • PSI Education Centre
    • Career Center
    • Support Program "PSI Career Return Program"
    • PSI-FELLOW/COFUND
  • Visit to PSIOpen mainmenu item
    • Overview
    • Visitor Centre psi forum
    • Schülerlabor iLab
    • Public Events
    • How to find us
  • About PSIOpen mainmenu item
    • PSI in brief
    • Strategy
    • Guiding principles
    • Facts and figures
    • Organisational structure
    • For the media
    • Suppliers and customers
    • Customers E-Billing
  • DE
  • EN
  • FR

Digital User Office (mobile)

  • Digital User Office

You are here:

  1. PSI Home
  2. Our Research
  3. Current topics from our research
  4. Drug development

Secondary navigation

Our Research

  • Current topics from our research Expanded submenu item
    • Matter and Material
    • Human Health
    • Energy and Environment
    • ESI Platform
    • Large research facilities
    • Project SLS 2.0
    • Topic Overview
    • Archive
  • 5232 – The magazine of the Paul Scherrer Institute
    • Contact
  • Brochures
  • Films
    • Virtual Tour
  • Media corner
    • Media Releases
    • Social Media Newsroom
×

Info message

This is a text from the PSI media archive. The contents may be out-of-date.
5 September 2008

Promising targets for drug development

Media Releases Human Health Biology

ETH Researchers determine atomic structure of the mammalian fatty acid factory

Zurich, 4 September 2008.

Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is a promising target for the development of anti-cancer and anti-obesity drugs and for the treatment of metabolic disorders. Researchers of ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase.

Synthesis of fatty acids is a central cellular process that has been studied for many decades. Fatty acids are used in the cell as energy storage compounds, messenger molecules and as building blocks for the cellular envelope. Previously, individual steps of this process have been investigated using isolated bacterial enzymes. However, in higher organisms – except plants – fatty acid synthesis is catalyzed by large multifunctional proteins where many individual enzymes are brought together to form a molecular assembly line.

The atomic structure of a mammalian fatty acid factory is the result of many years of research at ETH Zurich

As described in this week's issue of Science magazine, researchers at ETH Zurich, supported by the National Centre of Excellence in Research (NCCR) in Structural Biology of the Swiss National Science Foundation, determined the high-resolution structure of a mammalian fatty acid synthase using data collected at the Swiss Light Source (SLS) of the Paul Scherrer Institute (PSI). These results crown the efforts towards determining detailed structures of fatty acid synthases in higher organisms, a milestone for future investigations, that a relatively small group of scientist at ETH Zurich, consisting of Timm Maier, Marc Leibundgut and Simon Jenni in the laboratory of Prof. Ban, have been pursuing for a number of years. This topic of research was initiated at ETH in 2001 and the first papers describing architectures of fungal and mammalian fatty acid synthases appeared two years ago in Science. Last year, the atomic structures of two fungal fatty acid synthases and the mechanism of substrate shuttling and delivery in these multi-enzymes were published in the same magazine. The latest paper in this series describes the atomic structure of the mammalian fatty acid synthase. These results reveal the details of all catalytic active sites responsible for iterative fatty acid synthesis and show how the flexibility of this large multi-enzyme is used for transferring substrates from one enzymatic active site to the next.

Fatty acid synthases as drug targets?

Besides the fundamental scientific interest in the function of this multi-enzyme with a central role in primary metabolism, mammalian fatty acid synthase is also considered a promising drug target. Although most fat accumulated in animals and humans is delivered to cells by ingestion and not by de novo synthesis, compounds that inhibit the function of the mammalian fatty acid synthase induce weight reduction in animals, showing potential for the treatment of obesity and obesity-related diseases, such as diabetes and coronary disorders. Furthermore, due to the increased requirement for fatty acid synthesis in cancer cells, inhibitors of this enzyme have anti-tumor activity, making fatty acid synthase an attractive drug target for anti-cancer therapy.

Multi-enzymes: the ultimate organic chemists

Mammalian fatty acid synthase belongs to a large family of multi-enzymes, some of which are responsible for synthesis of complex natural products of outstanding medical relevance with antibiotic, anticancer, antifungal and immunosuppressive properties. The structure of mammalian fatty acid synthase reveals how different catalytic domains are excised or inserted in various members of this family to yield multi-enzymes capable of synthesizing a large variety of chemical products. It facilitates the design of novel molecular assembly lines for the production of novel compounds. In particular, engineering of novel multi-enzymes for the production of modified antibiotics is important in the fight against resistant strains of bacteria.

Contact:

Clemens Schulze-Briese
Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
E-Mail: clemens.schulze@psi.ch; Phone: +41 56 310 45 33

Furter Information:

ETH Life: http://www.ethlife.ethz.ch/archive_articles/080905_Ban_Paper_Synthase/index

Science: http://www.sciencemag.org/cgi/content/abstract/321/5894/1315
Images
Darstellung der zyklischen Fettsäure-Herstellung durch die Fettsäure-Synthase der Säugetiere
Darstellung der zyklischen Fettsäure-Herstellung durch die Fettsäure-Synthase der Säugetiere

Click on the download icon to download the high resolution version.

Sidebar

5232 01/2021

5232 — Das Magazin des Paul Scherrer Instituts

01/2021
in German
View in issuu.com
Download

Visitor Centre psi forum

Experience research live


The iLab School Laboratory

Experience Science - Explore Research

top

Footer

Paul Scherrer Institut

Forschungsstrasse 111
5232 Villigen PSI
Switzerland

Telephone: +41 56 310 21 11
Telefax: +41 56 310 21 99

How to find us
Contact

Visitor Centre psi forum
School Lab iLab (in German)
Center for Proton Therapy
PSI Education Centre
PSI Guest House
PSI Gastronomie (in German)

 

Service & Support

  • Phone Book
  • User Office
  • Accelerator Status
  • PSI Publications
  • Suppliers
  • E-Billing
  • Computing
  • Safety (in German)

Career

  • Working at PSI
  • Job Opportunities
  • Training and further education
  • Vocational Training (in German)
  • PSI Education Center

For the media

  • PSI in brief
  • Facts and Figures
  • Media corner
  • Media Releases
  • Social Media Newsroom

Follow us: Twitter (in English) LinkedIn Youtube Issuu RSS

Footer legal

  • Imprint
  • Terms and Conditions
  • Editors' login